MDM2 and cancer: Normally, these relevant genes encode RPs that decrease MDM2 E3 ligase activity by binding to MDM2, and they further affect p53 stability and promote cell cycle stagnation, thereby decreasing the risk of cancers (Daftuar et al., 2013).